IBA, Framatome Form Joint Venture to Produce Astatine-211 for Cancer Therapies

By Public Technologies
  • IBA and Framatome formed Ekalia, a jointly owned venture to industrialize astatine-211 production for targeted cancer therapies.
  • The venture plans a production network across Europe and North America, combining cyclotron technology with nuclear industrial expertise.
  • Its first site in Nantes, France, is expected to become operational in 2028.
  • A second pilot site is planned in the United States, followed by additional sites across Europe and the United States.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBA - Ion Beam Applications SA published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.